| Autor: |
Rodriguez, Franklin Castillero, Castillo-Fernandez, Omar, Lim-Law, Maria, Palacios, Cristiane Martin, Montano, Lilian, Benitez, Stephanie, Samudio, Jaime |
| Zdroj: |
Breast Cancer Management; May 2021, Vol. 10 Issue: 1 |
| Abstrakt: |
The aim of this study is to determine the effectiveness of subcutaneous trastuzumab in combination with intravenous pertuzumab and chemotherapy for patients with HER2-overexpressing localized breast cancer treated in our center. Methods:This was a descriptive, retrospective, real-world study. Results:Of 156 patients, pathological complete response (pCR) was achieved in 64.1%. A multivariate analysis showed a relationship with a negative hormone receptor (HR) expression and a HER2 score of 3+ by immunohistochemistry. Relapse-free survival (RFS) was higher in patients with pCR. Conclusion:Neoadjuvant therapy with dual blockade using intravenous pertuzumab and subcutaneous trastuzumab for HER2+ localized breast cancer in routine clinical practice resulted in a 64.1% pCR rate. Additionally, this outcome was related to a negative HR expression and HER2 overexpression, and correlated with higher relapse-free survival. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
